Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).

Authors

Neeraj Agarwal

Neeraj Agarwal

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Neeraj Agarwal , Arun Azad , Karim Fizazi , Joaquin Mateo , Nobuaki Matsubara , Neal D. Shore , Jayeta Chakrabarti , Hsiang-Chun Chen , Silvana Lanzalone , Alexander Niyazov , Fred Saad

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT04821622

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS221)

DOI

10.1200/JCO.2022.40.6_suppl.TPS221

Abstract #

TPS221

Poster Bd #

R3

Abstract Disclosures